Ranbaxy's Synriam wins ASSOCHAM innovation award

As per IMS data, over 2 million pills of this new anti-malaria drug Synriam have been sold since its launch and over 700,000 patients have been treated in India

ranbaxy

(Left to Right) Dr Nilanjan Saha, vice president - medical, global marketing, Ranbaxy and Umang Chaturvedi, global head, corporate affairs, Ranbaxy receiving the award from S. Jaipal Reddy, minister for science and technology

Ranbaxy Laboratories, India's largest pharmaceutical company, on July 14, 2013 announced that it has been conferred with the Innovation Excellence Platinum Award at the ASSOCHAM Innovation Awards 2013 in the Science & Technology category for its new anti-malaria drug, SynriamTM. The prestigious award was given by Minister for Science & Technology and Earth Sciences, S Jaipal Reddy.

The objective of the ASSOCHAM Innovation Awards is to identify and bring forward innovative organisations in India who through their innovative actions have launched breakthrough changes and can become role models for others to emulate.

India's First New Drug, SynriamTM, was launched by Ranbaxy last year on April 25th (World Malaria Day).The drug is used for the treatment of plasmodium falciparum malaria, in adults. Ranbaxy is working to make this new treatment available in African, Asian and South American markets where Malaria is rampant. The company plans to submit New Drug Applications for market authorisation of SynriamTM in various African countriesin 2013. The company also has plans to extend the benefits of SynriamTM to children in the malaria endemic zones of Asia and Africa.

According to the IMS data, over 2 million SynriamTM pills have been sold since its launch and over 700,000 patients have been treated in India.

SynriamTM is the new ray of hope to the millions likely to get affected by malaria. The drug is efficacious and has the advantage of "compliance and convenience". The course is one tablet a day for three days and costs Rs 130. Unlike artemisinin-based drugs, it has a synthetic source, the production of which can be scaled up whenever required and a consistent supply of the drug can be maintained at low cost. The drug is also independent of dietary restrictions for fatty foods or milk, as is the case with other anti-malarial therapies.

Malaria is a major public health problem in more than 90 countries that host about 40% of the global population. The deadly disease is estimated to cause up to 250 million new infections worldwide every year.

Last year, SynriamTM won the Golden Peacock Innovative Product/Service Award.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X